Our Mission: Innovating to Protect Humanity from the Global Threat of Antimicrobial Resistance: Integrating Solutions Across Human and Veterinary Medicine, Stewardship, and Awareness
Pharma Firms Join Forces, Pledging $1 Billion for a Global ‘AMR Action Fund’ Aiming to Create a Sustainable Antibiotics Pipeline
July 30, 2020
WASHINGTON, D.C. – On July 9, the AMR Action Fund, a ground-breaking partnership that aims to bring 2-4 new antibiotics to patients by 2030, launched during a live, virtual event in Washington, D.C.
Novel antibiotics are urgently needed to address the rapid rise of antibiotic-resistant infections – also called antimicrobial resistance, or AMR. More than 20 leading biopharmaceutical companies have stepped up to the challenge and raised nearly US$1 billion in funding to support R&D of innovative new antibiotics to address the most resistant bacteria and life-threatening infections. The Fund will bridge innovative candidates in the pipeline through the most challenging later stages of drug development – with both funding and technical support – ultimately providing governments time to make the necessary policy reforms to enable a sustainable antibiotic pipeline and safeguard our future.
The event featured remarks from Dave Ricks, CEO of Eli Lilly and Company, Ken Frazier, CEO of Merck, Albert Bourla, CEO of Pfizer, Steve Ubl of PhRMA, and Michelle McMurray-Heath of BIO. Later in the event, policymakers and key AMR stakeholders underscored the threat of AMR and the importance of the new initiative.
A panel of key stakeholders included CIMAR Director Helen Boucher, MD, (IDSA, PACCARB, Tufts Medical Center); Scott Gottleib, American Enterprise Institute and former FDA Commissioner; Kathy Talkington, The Pew Charitable Trusts; Kevin Outterson, CARB-X; Ramani Varanasi, X-Biotix; and Michael Boyd, Cystic Fibrosis Foundation. In total, the D.C. launch event attracted approximately 1,000 viewers.
You can watch the event below or learn more here.